Who Owns Annexon Company?

Who controls Annexon Biosciences today?

Annexon’s June 2024 Phase 3 win and subsequent $125,000,000 raise reshaped ownership, shifting the cap table toward large institutional investors and strategic insiders. Market cap ranged between $700,000,000 and $950,000,000 in early 2025, reflecting its move toward commercialization.

Founders and early healthcare VCs provided initial control, but post-IPO and the 2024 financing concentrated voting power with major asset managers, the Board, and company insiders; see Annexon Porter's Five Forces Analysis for strategic context.

Annexon Biosciences was founded in 2011 by Arnon Rosenthal, Ph.D., and the late Ben Barres, M.D., Ph.D., to commercialize research on the C1q protein and synaptic pruning; early ownership centered on the founders, lead investors, and key scientific leadership.

Founders

Arnon Rosenthal and Ben Barres established the company in 2011 to translate C1q research into therapeutics.

Initial Equity Split

Equity was primarily held by founders and institutional backers, with founders retaining significant stakes and voting influence.

Lead Investor

New Enterprise Associates led the Series A and shaped early governance and ownership rights.

Other Early Backers

Clarus Ventures (now part of Blackstone Life Sciences) and additional VCs joined NEA in initial rounds.

Governance

Board seats were allocated to venture partners to provide oversight while preserving scientific control for founders.

Employee Equity

Early employees were on standard four-year vesting schedules to align incentives for long drug-development timelines.

Early contractual protections included anti-dilution provisions and buy-sell clauses for share transfers, and filings indicate NEA and early investors collectively held upwards of 60% of voting interest prior to later private financings.

Key Early Ownership Facts

Founders and venture partners structured Annexon ownership to advance C1q-focused programs without internal disputes.

• Founded in 2011 by Arnon Rosenthal and Ben Barres
• Series A led by New Enterprise Associates (NEA)
• Clarus Ventures among early backers
• NEA and early investors held > 60% voting interest per historical filings

For more on the company’s mission and values see Mission, Vision & Core Values of Annexon

Complete Annexon Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

Key events reshaping Annexon ownership include the July 24, 2020 IPO that raised about $250,000,000, subsequent secondary offerings to fund clinical programs, and a June 2024 follow-on that raised $125,000,000, expanding shares outstanding to ~110,000,000 by early 2025 and shifting control toward institutional holders.

Institutional investors now dominate Annexon ownership, with healthcare-focused funds steering strategy toward higher-probability commercial programs and large asset managers providing index-based exposure.

Major shareholders and strategic effects

Concentration among specialist investors has concentrated strategic priorities and amplified sensitivity to clinical outcomes.

• Bain Capital Life Sciences: ~12.5%
• New Enterprise Associates (NEA): ~9.2%
• Blackstone Life Sciences funds: ~8.5%
• Redmile Group: ~7.1%
• Vanguard + BlackRock combined: ~11% (index/fund positions)
• Institutional ownership overall: ~88%

Ownership evolution—documented in SEC filings and reflected in the company’s public float—means Annexon investors now primarily comprise specialist healthcare funds and large asset managers; see additional context in Marketing Strategy of Annexon.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

Annexon’s board combines founding leadership and major investor representatives, with Arnon Rosenthal remaining influential and William H. Carson, M.D. serving as Chairman alongside representatives from Bain Capital, NEA, and Satter Investment Management.

Annexon’s single-class common stock grants one vote per share, aligning voting power with economic ownership; however, institutional holders controlling nearly 40% of shares effectively determine outcomes for director elections and major transactions.

Board composition and voting dynamics

The board reflects both scientific leadership and top investors, concentrating control but providing continuity as Annexon moves toward commercialization.

• Single-class share structure: one vote per share
• Top institutions hold ~40% of stock, amplifying Annexon ownership influence
• Board seats include investor representatives from Bain Capital, NEA, and Satter
• A small consortium of three–four funds can block or approve major deals

For additional context on investor alignment and market focus, see Target Market of Annexon.

Annexon Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past 36 months Annexon ownership has shifted from concentrated venture-capital stakes toward larger institutional and thematic healthcare investors, driven by ANX005 Phase 3 success in mid-2024 and a post-trial capital inflow that reshaped the shareholder mix.

Analysts cite elevated M&A speculation as larger pharma targets neurology assets ahead of patent cliffs; the board faces potential fiduciary tests if a buyout surfaces around expected regulatory milestones in late 2025–early 2026.

Institutional concentration

Top institutional holders now account for a large share of float, increasing takeover sensitivity and secondary-market volatility.

Event-driven positioning

Hedge funds and late-stage healthcare investors are likely to increase positions ahead of the BLA for ANX005.

Capital runway

With approximately $350,000,000 on hand in early 2025, management plans to fund commercial launch activities and C1q platform trials without immediate equity raises.

Ownership outlook

Watch for consolidation among the top five shareholders; for context on company origins and earlier ownership shifts see Brief History of Annexon.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE